Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Recurrence × TP protocol × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Esophageal Neoplasms 3 Uterine Cervical Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Recurrence 1 Pathologic Complete Response 1 Neoplasm Metastasis 1 Melanoma 1 Lymphatic Metastasis 1 Esophageal Squamous Cell Carcinoma 1 Carcinoma, Squamous Cell 1 Breast Neoplasms 1

Interventions

Cyclophosphamide 16 fludarabine 12 Cisplatin 11 Rituximab 9 Dexamethasone 9 Gemcitabine 8 Cytarabine 7 fludarabine phosphate 6 Paclitaxel 6 N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 6 Lenalidomide 6 Decitabine 6 Radiotherapy 5 Etoposide 5 Carboplatin 5 Bendamustine Hydrochloride 5 camrelizumab 4 apatinib 4 Valproic Acid 4 Thalidomide 4 Procarbazine 4 Oxaliplatin 4 Injections 4 Bortezomib 4 Antilymphocyte Serum 4 tislelizumab 3 pomalidomide 3 Vinorelbine 3 Vinblastine 3 Radiosurgery 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01405235 2012-04-12

AGO-Zervix-1

Institut fuer Frauengesundheit

Phase 3 Unknown

Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡